The Global Breast Cancer Therapeutics Market, which stood at US$ 17,868.8 Mn in 2018, will reach [US$ 38,573.5 Mn] by the end of 2026. If these figures prove true, the global breast cancer therapeutics market will rise at a CAGR of 10.2% between 2018 and 2026.
“Some of the Main Key Players Covered in the Report”Â
- Genentech (F. Hoffmann-La Roche Ltd)
- Eli Lilly and Company
- Celgene Corporation
- Pfizer Inc
- Eisai Co. Ltd.
- Kyowa Kirin
- Bristol Myers Squibb
- Mayne Pharma Group Limited
- Valeant Pharmaceuticals
“Looming Patent Expiries Fuels Demand for Generic Drugs”
According to the World Health Organization, in 2018, an approximate of 627,000 women, which is tantamount to 15% of all cancer deaths worldwide, succumbed to breast cancer. The rising incidence of breast cancer is one of the chief drivers of the global breast cancer therapeutics market.
Browse Complete Report Details @Â https://www.fortunebusinessinsights.com/industry-reports/breast-cancer-therapeutics-market-100163
The global breast cancer therapeutics market is likely to witness the prevalence of high competition. According to the report, Genentech, Inc. (F. Hoffmann-La Roche Ltd) held the dominant share in the market in 2018. Its diverse product portfolio backs growth of the company in a targeted and chemotherapy segment.
With the expiry of most patent drugs in the market, there is an increased demand for their generic counterparts. Such factors are propelling vendors to invest more in research and development and develop generic drugs for breast cancer treatment. The introduction of combination drug therapy is anticipated to create better growth opportunities for the market.
- Targeted Therapy
- Ado-Trastuzumab Emtansine
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Cancer Type
- Hormone Receptor
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Order Full Report @ https://www.fortunebusinessinsights.com/checkout-page/100163
“High Intake of Oral Contraceptives Among Women, Boosting Market”
Breast cancer can develop due to reasons such as reduced breastfeeding, rise in the age of childbearing, undergoing estrogen modifying drug treatments and high intake of oral contraceptive pills. The increase in the number of women complaining of such problems and the successive rise in the number of breast cancer cases are factors boosting the global market for breast cancer therapeutics during the forecast period.
Another factor in creating lucrative growth opportunities for breast cancer therapies is the increasing number of obese women. With a change in lifestyle and unhealthy food habits, the rate of obesity is increasing by the day. Obesity further causes various health problems such as cardiovascular disorders, gall bladder diseases, diabetes, breathing problems, and breast cancer, among others.
Some of the players operating in the global breast cancer therapeutics market are Puma Biotechnology, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc., Eli Lilly and Company, Novartis International AG, AstraZeneca plc, F. Hoffmann-La Roche Ltd., Sanofi S.A.,GlaxoSmithKline plc, and Pfizer, Inc.
“Major Table of Content for Breast Cancer Therapeutics Market”
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions andAssumptions
- Executive Summary
- Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
- Key Insights
4.1 Prevalence of BreastCancer Therapeutics by Key Countries
4.2 Regulatory Scenario byKey Regions
4.3 Key IndustryDevelopments
4.4 Overview of CurrentAdvances in R&D for Breast Cancer Therapeutics
More Trending Topics from Fortune Business Insights: